In clinical practice, the more commonly targeted tumor markers include one of the epidermal growth factor receptors, EGFR, Her-2 receptor, and vascular endothelial growth factor receptor.
The effectiveness of targeted therapeutic drugs is closely related to the state of the molecular targets in the tumor cells.
Simply put, a target is like this: the drug is the bullet, and the tumor is the enemy. To eliminate the enemy effectively, one must hit the bullet right on the target.
Normally, the more targets there are, the better the therapeutic results.
Take, for example, "Regorafenib" in the digestive tract field, which targets VEGFR1, VEGFR2, VEGFR3, TIE-1, TIE-2, RAF-1, BRAF, BRAFV600, KIT, RET, PDGFR, FGFR, and so on.
There's a reason for this!
And this time!
The key issue lies here.
Their targeted drugs indeed had more targets.
But!
Remember, having targets is not necessarily bad!
What does that mean?
